About CytunePharma
CytunePharma is a Healthcare company based in Nantes (France) founded in 2007, and was acquired by Sotio in August 2018. Immunostimulatory agents and conjugated monoclonal antibodies for cancer are developed. CytunePharma has raised $7.84 million across 3 funding rounds from investors including SOTIO, PPF Group and Starquest Capital. The company was acqui-hired. Its focus areas include Life Sciences, Immunotherapy, Cytokines and Oncology.
Company details
Cytune Pharma is focussed on developing immunotherapies for cancer. It is developing therapies based on the reset, restore and activation of the antitumor immune system. Its lead product CYP0150 is a recombinant protein consisting of a human IL-15 linked to the Sushi domain of the human alpha chain receptor which stimulates natural killer and cytotoxic cells, without activating regulatory T cells that dampen the immune response. The candidate along with other immunotherapy strategies, such as checkpoint inhibitors claims to have shown effective and is currently in preclinical trials. It is planning to enter phase 1 trials in 2017. It is also developing conjugated monoclonal antibodies linked to CYP 0150.
- Headquarters Nantes, France
- Stage Acquired
- SectorsHealthcare
- Website cytunepharma.com
- Social LinkedIn
- Acquired by Sotio (Aug 2018)
Funding Insights of CytunePharma
CytunePharma has successfully raised a total of $7.84M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $6.6 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.84M
- Total Rounds 3
- Last Round Series B — $6.6M
- First Round $1.24M
(Jun 2012)
- Investors Count 2
All 3 funding rounds of CytunePharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2016 | $6.6M | Series B | – | – | |
| Feb 2015 | Series A | – | – | ||
| Jun 2012 | $1.24M | Seed | – | – |
3 investors in total: 3 institutional.
Investors in CytunePharma
CytunePharma has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include SOTIO, PPF Group and Starquest Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PPF Group is engaged in international investment across diverse sectors. | 1991 | ppf.eu | Prague, Czech Republic | |
Investments in Europe and US are made by Starquest Capital. | starquest-capital.com | Paris, France | ||
Activated dendritic cells are developed for cancer immunotherapy treatments. | 2010 | sotio.com | Prague, Czech Republic |
Investor details for CytunePharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of CytunePharma
4 dated milestones of CytunePharma across 11 years, from founding to its latest funding, stage changes and deals.
- Founded CytunePharma is founded.
- Funding First funding round of $1.2M.
- Funding Latest funding round, Series B, of $6.6M.
- Exit Acquired by Sotio.
Web traffic of CytunePharma
Websites that share an audience with CytunePharma (cytunepharma.com).
Websites whose visitors overlap most with CytunePharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cytunepharma
Complete news archive for CytunePharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CytunePharma
CytunePharma was founded in 2007 and raised its 1st funding round 5 years after it was founded.
CytunePharma is headquartered in Nantes, France. It is registered at Nantes, Pays De La Loire, France.
CytunePharma is a funded company, having raised a total of $7.84M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1.24M, raised on Jun 2012.
Cytune Pharma is focussed on developing immunotherapies for cancer. It is developing therapies based on the reset, restore and activation of the antitumor immune system. Its lead product CYP0150 is a recombinant protein consisting of a human IL-15 linked to the Sushi domain of the human alpha chain receptor which stimulates natural killer and cytotoxic cells, without activating regulatory T cells that dampen the immune response. The candidate along with other immunotherapy strategies, such as checkpoint inhibitors claims to have shown effective and is currently in preclinical trials. It is planning to enter phase 1 trials in 2017. It is also developing conjugated monoclonal antibodies linked to CYP 0150.
CytunePharma has 3 investors. Key investors include SOTIO, PPF Group, and Starquest Capital.
Yes. CytunePharma was acquired by Sotio in August 2018.